Lidcombe Program telehealth treatment for children 6-12 years of age: A Phase II trial

被引:2
|
作者
Johnson, Georgina [1 ]
Onslow, Mark [2 ]
Carey, Brenda [2 ]
Jones, Mark [3 ]
Kefalianos, Elaina [1 ,4 ]
机构
[1] Univ Melbourne, Dept Audiol & Speech Pathol, 550 Swanston St, Carlton, Vic 3053, Australia
[2] Univ Technol Sydney, Australian Stuttering Res Ctr, Ultimo, NSW, Australia
[3] Bond Univ, Inst Evidence Based Healthcare, Robina, Qld, Australia
[4] Murdoch Childrens Res Inst, Speech & Language Grp, Parkville, Vic, Australia
关键词
School-age; Stuttering; Treatment; SELF-REPORTED EXPERIENCE; SOCIAL ANXIETY DISORDER; PSYCHOMETRIC PROPERTIES; FOLLOW-UP; STUTTER; IMPACT; SPEECH; PARENT; INTERVENTION; SATISFACTION;
D O I
10.1016/j.jfludis.2024.106057
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Background: For children older than 6 years who stutter, there is a gap in clinical research. This is an issue for speech-language pathologists because the tractability of stuttering decreases and the risk of long-term psychological consequences increase with age. Purpose: To report a Phase II trial of a telehealth version of the Lidcombe Program with school-age children. Methods: Participants were 37 children who stuttered, 6-12 years of age, from Australia, New Zealand, Hong Kong, and Singapore. Parents were trained by video telehealth how to deliver the Lidcombe Program to their child. Primary and secondary outcomes were stuttering severity and psychosocial functioning measured pre-treatment and at 6 months and 12 months after starting treatment. Parents submitted two 10-minute recordings of their child speaking in conversation, and three measures of anxiety, impact of stuttering, and communication attitude. Results: Six months after starting treatment, seven children (18.9%) attained Lidcombe Program Stage 2 criteria, 25 children (67.6%) showed a partial response to treatment, and five children (13.5%) showed no response. By 12 months, 12 children (32.4%) had reached Stage 2 criteria. Psychosocial improvements were observed 6 and 12 months after starting treatment. Conclusions: The Lidcombe Program may eliminate or nearly eliminate stuttering for about one third of children 6-12 years of age. Randomized controlled trials with this age group involving the Lidcombe Program are warranted. In the interim, the Lidcombe Program is a clinical option clinicians can implement with this age group to reduce stuttering and its psychosocial impacts.
引用
收藏
页数:13
相关论文
共 36 条
  • [31] A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
    Chu, Kai
    Hu, Yuemei
    Pan, Hongxing
    Wu, Jingliang
    Zhu, Dandan
    Young Jr, Mariano M. M.
    Luo, Li
    Yi, Zhuobiao
    Giardina, Peter C. C.
    Gruber, William C. C.
    Scott, Daniel A. A.
    Watson, Wendy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [32] Nutritional treatment of children 6-59 months with severely low weight-for-age z-score: a study protocol for a 3-arm randomized controlled trial
    Kangas, Suvi T.
    Ouedraogo, Cesaire T.
    Tounkara, Moctar
    Ouoluoguem, Bareye
    Coulibaly, Issa Niamanto
    Haidara, Alhousseyni
    Diarra, Niele Hawa
    Diassana, Koniba
    Tausanovitch, Zachary
    Ritz, Christian
    Wells, Jonathan C.
    Briend, Andre
    Myatt, Mark
    Radin, Elizabeth
    Bailey, Jeanette
    TRIALS, 2024, 25 (01)
  • [33] Long-Term Survival of Children Less than Six Years of Age Enrolled on the CCG-945 Phase III Trial for Newly-Diagnosed High-Grade Glioma: A Report From the Children's Oncology Group
    Batra, Vandana
    Sands, Stephen A.
    Holmes, Emi
    Geyer, Jeffrey Russell
    Yates, Allan
    Becker, Lawrence
    Burger, Peter
    Gilles, Floyd
    Wisoff, Jeffrey
    Allen, Jeffrey C.
    Pollack, Ian F.
    Finlay, Jonathan L.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 151 - 157
  • [34] An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6-to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?
    Firat, Sumeyra
    Gul, Hesna
    Aysev, Ayla
    JOURNAL OF ATTENTION DISORDERS, 2021, 25 (09) : 1321 - 1330
  • [35] Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
    Hammitt, Laura L.
    Quinn, Dean
    Janczewska, Ewa
    Pasquel, Francisco J.
    Tytus, Richard
    Reddy, K. Rajender
    Abarca, Katia
    Khaertynova, Ilsiyar M. M.
    Dagan, Ron
    Dawson, Rachel
    McCauley, Jennifer
    Shekar, Tulin
    Fu, Wei
    Pedley, Alison
    Sterling, Tina
    Tamms, Gretchen
    Musey, Luwy
    Buchwald, Ulrike K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [36] STUDY ESOGIA-GFPC 08-02-PHASE III, RANDOMIZED, MULTICENTER TRIAL INVOLVING SUBJECTS OVER 70 YEARS OF AGE WITH NON SMALL-CELL LUNG CANCER OF STAGE IV AND COMPARING A "CLASSICAL" STRATEGY OF TREATMENT ALLOCATION (DUAL-AGENT THERAPY BASED ON CARBOPLATIN OR MONOTHERAPY WITH DOCETAXEL ALONE), BASED ON PERFORMANCE STATUS AND AGE, WITH AN "OPTIMIZED" STRATEGY ALLOCATING THE SAME TREATMENTS ACCORDING TO A SIMPLIFIED GERIATRIC SCREENING SCALE, PLUS A MORE THOROUGH GERIATRIC EVALUATION IF NECESSARY.
    Corre, Romain
    Audigier-Valette, Clarisse
    Berard, Henri
    Falchero, Lionel
    Demattei, Christophe
    Le Caer, Herve
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S556 - S556